Back to Search Start Over

LBA61 HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: A multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC).

Authors :
Wang, L.
Qin, S.
Zhou, Y.
Zhang, S.
Sun, X.
Chen, Z.
Cui, J.
Zhao, P.
Gu, K.
Li, Z.
Wang, J.
Chen, X.
Yao, J.
Shen, L.
Zhou, J.
Wang, G.
Bai, Y.
Wang, Q.
Wang, H.
Source :
Annals of Oncology. 2022 Supplement 7, Vol. 33, pS1426-S1426. 1p.
Publication Year :
2022

Subjects

Subjects :
*CLINICAL trials
*PANCREATIC cancer
*METASTASIS
*PLACEBOS

Details

Language :
English
ISSN :
09237534
Volume :
33
Database :
Academic Search Index
Journal :
Annals of Oncology
Publication Type :
Academic Journal
Accession number :
159078764
Full Text :
https://doi.org/10.1016/j.annonc.2022.08.063
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details